MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of both low-dose oral (by
mouth) 17-ß-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in
reducing hot flashes. Included in this objective is the intention to compare venlafaxine XR
to estradiol therapy, to provide evidence of the relative efficacy of venlafaxine to what is
currently considered the most established but also a controversial therapy. 17-ß-estradiol is
a type of estrogen. Venlafaxine XR is the extended release (XR) version of venlafaxine.
Venlafaxine XR is an serotonin-norepinephrine reuptake inhibitor (SNRI). A placebo is a
substance containing no medication.
Phase:
N/A
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Center for Complementary and Integrative Health (NCCIH) National Institute on Aging (NIA) Office of Research on Women's Health (ORWH)